This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Sodium chloride & glucose parenteral

Presentation

Infusions containing sodium chloride and glucose.

Drugs List

  • glucose 10% and sodium chloride 0.18% infusion
  • glucose 2.5% and sodium chloride 0.45% infusion
  • glucose 4% and sodium chloride 0.18% infusion
  • glucose 5% and sodium chloride 0.45% infusion
  • glucose 5% and sodium chloride 0.9% infusion
  • Therapeutic Indications

    Uses

    Fluid replacement
    Sodium depletion
    Source of energy in parenteral nutrition

    Dosage

    The dosage must be determined by the physician and is dependant upon the age, weight and clinical condition of the patient.

    Solutions containing sodium chloride 0.18% and glucose 4% should not generally be used for fluid replacement in children because of the risk of hyponatraemia.

    The infusion rate should not exceed the patient's glucose oxidation capacities in order to avoid hyperglycaemia.

    Adults

    500ml to 3litres in 24 hours.

    Children

    Children aged 12 to 18 years: 500ml to 3litres in 24 hours.

    Administration

    The administration is performed by intravenous infusion.

    Contraindications

    Diabetic hyperosmolar coma
    Fluid retention
    Recent head trauma
    Cardiac failure
    Hepatic cirrhosis with ascites
    Hyperemesis gravidarum
    Hyperlactataemia
    Hypervolaemia
    Hypochloraemia
    Hyponatraemia
    Recent ischaemic cerebrovascular accident
    Severe hyperglycaemia
    Severe renal impairment
    Uncontrolled diabetes mellitus

    Precautions and Warnings

    Children under 18 years
    Debilitation
    Elderly
    Obesity
    Peripheral oedema
    Predisposition to hypokalaemia
    Restricted sodium intake
    Severe sepsis
    Breastfeeding
    Cardiac disorder
    Cardiac impairment
    Diabetes mellitus
    Eclampsia
    Electrolyte imbalance
    Gastrointestinal disorder
    Glucose-galactose malabsorption syndrome
    Hepatic cirrhosis
    Hepatic impairment
    Hyperaldosteronism
    Hypernatraemia
    Hypertension
    Malnutrition
    Metabolic alkalosis
    Pre-eclampsia
    Pregnancy
    Renal impairment
    Syndrome of Inappropriate Antidiuretic Hormone secretion
    Thiamine deficiency
    Thyrotoxicosis

    Sodium content of formulation may be significant
    Not all available brands are licensed for all age groups
    Potassium deficient patients should receive potassium supplements
    Contains glucose
    Avoid rapid infusion rates
    Child under 17 years: Treatment to be initiated/supervised by a specialist
    Rapid infusion of hypertonic sodium chloride may cause circulatory overload
    Diabetic control may need adjustment
    Monitor blood glucose periodically
    Monitor children closely for signs and symptoms of hyponatraemia
    Monitor fluid and electrolyte status
    Monitor fluid balance
    Treating severely undernourished patients may cause refeeding syndrome
    Consider dose reduction in renal impairment
    Consider reducing dose in elderly
    Avoid prolonged use

    Glucose intravenous infusions are usually isotonic solutions. However, glucose containing fluids can become extremely physiologically hypotonic due to rapid glucose metabolization. Intravenous administration of glucose can cause electrolyte disturbances like hypo- or hyperosmotic hyponatraemia.

    During the catabolic phase of the response to illness or injury, there is an increase in antidiuretic hormone, cortisol, and aldosterone secretion, especially if there has been any reduction in blood or extracellular fluid volume. In consequence, retention of sodium and water and loss of potassium occurs. This should be taken into consideration when administering a hypotonic solution.

    Solutions containing glucose should not be used routinely after ischaemic stroke, unless specifically required, as hyperglycaemia has been implicated in increasing cerebral ischaemic damage and impairing recovery.

    Pregnancy and Lactation

    Pregnancy

    Use sodium chloride and glucose with caution during pregnancy.

    The manufacturer advises caution if sodium chloride and glucose is used during pregnancy. Maternal hyperglycaemia in the perinatal period should be avoided to prevent the induction of reflex neonatal hypoglycaemia. Caution should be exercised when administering to pregnant women during labour, particularly if administered with oxytocin, due to the risk of hyponatraemia.

    Lactation

    Use sodium chloride and glucose with caution during breastfeeding.

    The manufacturer advises caution if sodium chloride and glucose is used when breastfeeding. The manufacturer states that potential risks and benefits should be considered for each patient before initiation of treatment. The presence of sodium chloride and glucose in human breast milk is unknown. Effects on exposed infants are unknown.

    Side Effects

    Anaphylactic reaction
    Chills
    Electrolyte disturbances
    Hyperglycaemia
    Hypersensitivity reactions
    Hypokalaemia
    Hypomagnesaemia
    Hyponatraemia
    Hypophosphataemia
    Infusion-related symptoms
    Local pain (injection site)
    Oedema
    Over-hydration
    Phlebitis
    Pruritus
    Pyrexia
    Rash
    Thrombophlebitis
    Thrombosis (injection site)
    Venous irritation
    Vesicles

    Overdosage

    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

    Further Information

    Last Full Review Date: November 2021

    Reference Sources

    Summary of Product Characteristics: Sodium Chloride 0.18% Glucose 4.0% IV infusion. Fresenius Kabi Ltd. Revised May 2016.

    Summary of Product Characteristics: Sodium Chloride 0.18% Glucose 10% IV infusion. Fresenius Kabi Ltd. Revised September 2009.

    Summary of Product Characteristics: Sodium Chloride 0.45% Glucose 2.5% IV infusion. Baxter Healthcare Ltd. Revised March 2019.

    Summary of Product Characteristics: Sodium Chloride 0.45% Glucose 5.0% IV infusion. Fresenius Kabi Ltd. Revised September 2009.

    Summary of Product Characteristics: Sodium Chloride 0.9% Glucose 5.0% IV infusion. Fresenius Kabi Ltd. Revised May 2016.

    NICE Evidence Services Available at: www.nice.org.uk Last accessed: 15 November 2021

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.